一个可解释的深度学习框架识别了阿尔茨海默病的蛋白质驱动因素
Elena Panizza1, Richard A Cerione1,2
1Department of Molecular Medicine, Cornell University, Ithaca, NY, United States.
Frontiers in cell and developmental biology
|October 2, 2024
概括
研究人员开发了EnsembleOmicsAE,这是阿尔茨海默病 (AD) 蛋白质组学的深度学习方法. 这种方法揭示了新型分子驱动器,如整合素信号传递,为AD病原体提供了新的见解.
科学领域:
- 神经科学是一个神经科学.
- 计算生物学 计算生物学
- 蛋白质组学是指蛋白质组学.
背景情况:
- 阿尔茨海默病 (AD) 是一种主要的神经退行性疾病,其病因不明确,没有治愈方法.
- 来自健康和AD个体的多omics数据可用,但机器学习模型往往缺乏可解释性.
- 阿尔茨海默氏症大脑的蛋白质基因格局比其遗传格局更难理解.
研究的目的:
- 开发一种可解释的深度学习方法,用于分析阿尔茨海默病中复杂的蛋白质组学数据.
- 为了确定新的分子驱动因素和信号通路,涉及到AD的病变发生.
- 探索蛋白质组变化与患者死亡年龄之间的关系.
主要方法:
- 开发了EnsembleOmicsAE,这是一组自动编码器的深度学习组合,以将蛋白质组学数据的复杂性降低到稳定的潜在特征.
- 结合了来自3个AD队伍559名个体的脑蛋白质组数据.
- 实施了一种代特征编码算法,以计算蛋白质特征的重要性,并识别富含蛋白质-蛋白质相互作用的信号模块.
主要成果:
- EnsembleOmicsAE产生了适合生物解释的稳定潜伏特征.
- 确定了新的AD分子驱动因素,包括因特林信号传递和细胞粘附,这些因素在线性方法中错过了.
- 确定信号模块和死亡年龄之间的特征关系,揭示了年轻人与老年阿兹海默症患者维门丁和MAPK信号的差异调节.
结论:
- EnsembleOmicsAE为阿尔茨海默病蛋白质组学研究提供了一个可解释的深度学习框架.
- 该方法成功地确定了以前未被识别的分子途径,这些途径有助于AD.
- 研究结果表明,在阿尔茨海默病患者中,与年龄相关的蛋白质特征有所不同,突出显示了维丁和MAPK信号.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.8K
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
779
相关概念视频
Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
